

Cloning and Sequence Analysis of Cytadhesin P1 Gene from *Mycoplasma pneumoniae*

C. J. SU, V. V. TRYON, AND J. B. BASEMAN*

Department of Microbiology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284

Received 31 July 1987/Accepted 12 September 1987

Mycoplasma pneumoniae cytadhesin P1 was purified by monoclonal antibody affinity chromatography followed by preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The N-terminal 18-amino-acid sequence of P1 was determined and used to design two synthetic oligonucleotides, a 14-mer corresponding to amino acids 1 to 5 and an 18-mer corresponding to amino acids 7 to 12. These oligonucleotides served as hybridization probes for the identification of the P1 gene by Southern blot analysis of *M. pneumoniae* DNA. The P1 gene was cloned into plasmid pUC19 and mapped by using appropriate restriction endonucleases. The DNA sequence of the entire P1 gene was determined by subcloning appropriate DNA fragments into bacteriophage M13 and sequencing the DNA by the dideoxy-chain-termination method. The P1 gene contains an open reading frame of 4,881 nucleotides coding for a protein of 1,627 amino acids with a calculated molecular weight of 176,288. Properties of the amino-terminal sequence suggest that protein P1 may be synthesized as a precursor with subsequent processing to a mature protein of a calculated molecular weight of 169,758. Potential antigenic sites were determined by hydrophilicity plots. A computer search revealed that part of the predicted P1 sequence is homologous to cytoskeletal keratin of mammalian species and human fibrinogen alpha chain precursor. These results demonstrate the uniqueness of P1 as a cytadhesin and virulence determinant.

Mycoplasma-mediated human disease represents a major class of infections which are poorly understood. *Mycoplasma pneumoniae*, the etiologic agent of primary atypical pneumonia, possesses a tiplike organelle which permits a highly oriented extracellular parasitism of the respiratory epithelium (5, 11, 26). A surface-localized, trypsin-sensitive protein designated P1 (165 kilodaltons [kDa]) clusters at the mycoplasma terminus and is essential for the cytoadherence event (1, 2, 6, 10). Mutants of *M. pneumoniae* which lack P1 or are unable to mobilize and anchor P1 at the tip are avirulent (1, 15, 16). Also, trypsin treatment of wild-type virulent mycoplasmas abrogates the functionality of P1 as an adhesin (1, 2, 10, 11, 23). Thus, it is well established that P1 is a critical virulence determinant but efforts to define structural-functional domains of this hydrophobic, integral membrane protein have failed.

Our previous attempts to clone the P1 gene by introducing recombinant molecules containing *M. pneumoniae* DNA into *E. coli* and screening immunologically for the expression of protein P1 were of limited success (31). This may be due to the premature termination of *M. pneumoniae* proteins in *Escherichia coli* since Yamao et al. (35) recently reported that in *Mycoplasma capricolum* TGA encodes tryptophan rather than a termination signal.

In this report we describe the cloning of the P1 gene using an approach which does not require expression of the P1 protein in *E. coli*. We also present the DNA sequence of the P1 gene and the deduced sequence of the P1 protein.

MATERIALS AND METHODS

Organisms and growth conditions. Virulent hemadsorbing *M. pneumoniae* M129 in the 16th broth passage was grown at 37°C in 32-oz. (ca. 946-ml) glass prescription bottles containing 70 ml of Edward medium as previously described (23).

Cells were harvested 72 h after inoculation and stored at -70°C.

E. coli HB101, DH5 α , and JM107 were purchased from commercial sources and grown in LB broth (20).

Purification of P1 protein by affinity chromatography. The P1 protein was purified by antibody affinity chromatography according to the method described previously by us (18). Four anti-P1 monoclonal antibodies secreted by independently derived hybridomas (23, 24) were combined and purified by protein A-Sephadex column chromatography. Anti-P1 affinity columns were prepared by coupling 50 mg of purified anti-P1 antibody to 15 ml of cyanogen bromide-activated Sephadex gel (Pharmacia Fine Chemicals, Piscataway, N.J.). Pellets from 100 bottles of *M. pneumoniae* were suspended in 50 ml of 20 mM Tris hydrochloride (pH 8.0), 0.2% sodium deoxycholate (Fisher Scientific Co., Pittsburgh, Pa.), 0.1% sodium dodecyl sulfate (SDS; BDH Chemicals, Poole, England), 10 mM EDTA, and 0.2% Triton X-100 containing 1 mM phenylmethylsulfonyl fluoride. Solubilization of proteins was assisted by passing the cell suspension through successively smaller-gauge needles (22 to 27 gauge). Insoluble material was removed by centrifugation at 100,000 $\times g$ for 30 min.

Solubilized proteins were applied to the affinity column at 4°C and washed with 5 column volumes of the same buffer minus sodium deoxycholate. Bound protein was eluted with 0.1 M acetic acid (pH 3) containing 0.15 M NaCl and 0.1% SDS. The eluted protein was immediately neutralized with 1.0 M Tris and concentrated in a pressure ultrafiltration concentrator (Amicon Corp., Danvers, Mass.).

The affinity column-derived P1 protein was further purified by preparative polyacrylamide gel electrophoresis (PAGE). After staining, the P1 protein band was cut out of the gel, electroeluted according to Hunkapiller et al. (12), and reprecipitated several times with 80% methanol at -20°C.

During the purification process, the amount of P1 protein was estimated by comparisons with known amounts of

* Corresponding author.

molecular weight standards (Bio-Rad Laboratories, Richmond, Calif.) after Coomassie blue staining.

N-terminal amino acid sequence determination of P1 protein. The purified P1 protein was sequenced from the amino terminus with a gas phase protein sequencer by C. Y. Yang in the Department of Medicine, Baylor College of Medicine, Houston, Tex. Approximately 50 µg of purified P1 was used (300 pmol) for each of three sequence analyses.

Oligonucleotide probes. Two oligonucleotide probes were designed on the basis of the N-terminal amino acid sequence of the P1 protein. These oligonucleotides were synthesized in the Department of Biochemistry, Baylor College of Medicine, and purified by electrophoresis in a 20% polyacrylamide gel containing 8 M urea (3). For use as hybridization probes, the oligonucleotides were labeled at the 5' end with [γ - 32 P]ATP by the T4-poly-nucleotide kinase reaction (20).

Southern blot analysis of *M. pneumoniae* DNA. *M. pneumoniae* DNA was prepared from exponentially growing cells as previously described (31). DNA (12 µg) was digested to completion with appropriate restriction enzymes before electrophoretic separation on 0.7% agarose gels. Gels were stained with ethidium bromide and photographed under UV illumination. DNA was transferred to nitrocellulose filter paper (30) with 20× SSC (1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate), rinsed once with 6× SSC, and then baked at 80°C for 2 h under vacuum. Filters were prehybridized overnight at 37°C in 20 ml of prehybridization solution containing 6× SSC, 60 mM sodium phosphate (pH 7.0), 5× Denhardt solution (bovine serum albumin, polyvinylpyrrolidone, Ficoll [Pharmacia] at 1 mg/ml), and 0.1 mg of denatured herring sperm DNA per ml. Hybridizations were done for 12 h in 10 ml of prehybridization solution plus 10% dextran sulfate and 32 P-labeled oligonucleotide probes (3×10^6 cpm) at 25°C (14 base pairs [bp], 14-mer) or 37°C (18 bp, 18-mer). After incubation, filters were rinsed twice with 6× SSC at 4°C (30 min each) and then washed twice in wash solution (3 M tetramethylammonium chloride, 50 mM Tris hydrochloride [pH 8.0], 2 mM EDTA, 0.1% SDS) at the appropriate temperature (14-mer at 37°C and 18-mer at 45°C) for 20 min (34). After being washed, filters were rinsed in 6× SSC at 4°C, dried, and exposed to X-ray film using an intensifying screen.

Cloning of *M. pneumoniae* P1 gene. *M. pneumoniae* DNA (500 µg) was digested to completion with selected restriction enzymes and electrophoresed in 0.7% agarose gels. The DNA of the size range which hybridized to both the 14- and 18-bp oligonucleotide probes was purified by electrophoresis onto DE-81 paper, eluted from the paper with 20 mM Tris hydrochloride, pH 8.0, and 1.5 M NaCl, precipitated with ethanol, and redissolved in TE buffer (20).

Plasmids pUC9 and pUC19 were used as cloning vectors. Vectors were digested with appropriate restriction enzymes, and the 5'-end phosphate was removed by calf intestinal alkaline phosphatase (20). Mycoplasma DNA and vector were mixed at 1:1 molar ratios and ligated at room temperature for 4 h with T4 DNA ligase (20). After incubation the reaction was stopped by adding EDTA to 10 mM and diluted fivefold with distilled H₂O, and the DNA was used to transform competent HB101 or DH5 α *E. coli* cells according to the instructions of the manufacturer (Bethesda Research Laboratories, Inc., Gaithersburg, Md.). Transformants were selected on LB agar plates containing 50 µg of ampicillin per ml. Individual colonies were picked and grown overnight in 5 ml of LB broth containing 50 µg of ampicillin per ml. Plasmid DNA was isolated from overnight cultures by the alkaline lysis method (13) and analyzed on agarose gels. To

determine which insert-containing plasmids carried the P1 gene, plasmid DNAs were blotted onto nitrocellulose filters. The filters were then hybridized to the 32 P-labeled 18-mer oligonucleotide probes, washed, and exposed to film as described above.

DNA sequencing. DNA sequences were determined by the dideoxy-chain-termination method of Sanger et al. (29). M13 sequencing kits were purchased from Bethesda Research Laboratories, and the reactions were performed according to the instructions of the manufacturer, except that deoxy-7-deaza GTP (Boehringer Mannheim Biochemicals, Indianapolis, Ind.) was used in sequencing reactions in place of dGTP (22). Some DNA fragments were sequenced by subcloning appropriate restriction enzyme fragments into an M13 bacteriophage vector (21), and the single-stranded DNA was purified for use as a sequencing template. To sequence the rest of the P1 gene, a large piece of DNA was subcloned into an M13 vector and a series of deletions from the 3' end were generated by treating the double-stranded DNA with exonuclease III according to the method of Henikoff (8). Subclones with progressive deletions were selected for use as sequencing templates. Both strands of the entire P1 gene were sequenced. Nucleic acid and protein computer analyses were performed by using the Microgenie program (Beckman Instruments, Inc., Palo Alto, Calif.). Comparisons of the P1 DNA and deduced protein sequences were with the most recent releases of the National Institutes of Health GenBank DNA sequence database and the National Biomedical Research Foundation protein sequence database, respectively.

RESULTS

Purification of P1. *M. pneumoniae* cytoadhesin protein P1 (165 kDa) was isolated by using monoclonal antibody affinity chromatography as an initial step. Immunoaffinity chromatography selectively enriched for the expected 165-kDa species (Fig. 1A to C). Approximately 400 µg of P1 protein was recovered after the immunoaffinity step from an initial *M. pneumoniae* extract containing 300 mg of total protein. The affinity column-purified P1 was further processed by preparative gel electrophoresis through a 5% polyacrylamide-SDS gel, and the 165-kDa protein was recovered by electroelution. About 60% recovery was achieved after 24 h of elution at room temperature in 50 mM ammonium carbonate containing 0.1% SDS. The eluted protein was then precipitated in 80% methanol to remove SDS. SDS-PAGE analysis of the recovered P1 revealed that the sample contained intact P1 protein (Fig. 1D), and the gel was deliberately overloaded to show the purity of the sample. Finally, the purified protein was shown to be P1 since it reacted with anti-P1 monoclonal antibodies in Western blot analyses (data not shown).

Generation of oligonucleotide probes. The amino-terminal amino acid sequence of P1 protein was determined by gas phase microsequencing. Three separate determinations yielded the sequence shown in Fig. 2. Two oligonucleotide probes complementary to all the possible mRNA combinations encoding different portions of the protein were synthesized, a 14-mer corresponding to amino acids 1 to 5 and an 18-mer corresponding to amino acids 7 to 12 (Fig. 2). Because *M. pneumoniae* may use TGA instead of TGG to encode tryptophan, both C and T were used in the third position of the tryptophan codon of the 18-bp oligonucleotide.

Cloning of the P1 gene. The synthetic oligonucleotides were used to probe the *M. pneumoniae* genome for the P1




FIG. 1. SDS-PAGE analysis of protein samples during the purification of P1. (A) Total protein extract from *M. pneumoniae*. Arrow at right indicates the position of P1. (B) Same sample as in panel A after a single passage through the anti-P1 affinity column. (C) Protein eluted from the anti-P1 affinity column. (D) P1 after preparative gel electrophoresis and electroelution. Proteins were separated by 7.5% PAGE and stained with Coomassie blue.




FIG. 3. *M. pneumoniae* DNA (12 µg per lane) digested with different restriction enzymes and separated by 0.7% agarose gel electrophoresis. Lanes: A, standard; B, *EcoRI*; C, *HaeIII*; D, *PstI*; E, *HindIII*; F, *BamHI*; G, *KpnI*; H, *Sall*.

gene. *M. pneumoniae* DNA was digested overnight with several restriction endonucleases and separated by 0.7% agarose gel electrophoresis (Fig. 3). These DNAs were transferred to nitrocellulose filters and exposed to the 14- and 18-bp oligonucleotide probes. Both probes hybridized to several DNA bands in each digestion. A 4.3-kilobase (kb) *HindIII* fragment hybridized most intensely to both the 14-mer and 18-mer (Fig. 4), strongly implicating this DNA fragment as containing the N-terminal sequence of P1.

To clone this DNA fragment, *M. pneumoniae* DNA was

digested with *HindIII*, separated by agarose gel electrophoresis, and stained briefly with ethidium bromide. DNA in the 4.3-kb size range was eluted from the gel. The DNA was then ligated into the *HindIII* site of pUC9 and transformed into *E. coli* HB101. About 5,000 transformants were obtained, of which 200 transformants were picked, and their plasmid DNA was isolated and analyzed on agarose gels to




FIG. 2. The N-terminal 18-amino-acid sequence of protein P1 and the 14-mer and 18-mer oligonucleotide probes designed to hybridize to the P1 gene. The 14-mer covers amino acids 1 to 5, and the 18-mer covers amino acids 7 to 12. X = ACGT.




FIG. 4. Southern blot analysis of *M. pneumoniae* genome. *M. pneumoniae* DNA was digested with *HindIII*, separated by 0.7% agarose electrophoresis, and transferred to nitrocellulose paper according to the method of Southern (30). The nitrocellulose strip was then hybridized to the 14-mer (A) and 18-mer (B) probes labeled with ³²P. A single band (4.3 kb) hybridizes to both probes (arrow).





FIG. 5. Restriction enzyme map of the P1 gene. The first clone (62A) contains the 4.3-kb *Hind*III piece, and the second clone contains the 6-kb *Eco*RI piece. Both the 14-mer and 18-mer probes hybridize to the DNA at a site very close to the first *Sma*I site. Symbol: , P1 structural gene.

check for insert size. DNAs from 40 plasmids with inserts in the 4- to 5-kb range were blotted onto nitrocellulose paper and hybridized with the 14-mer and 18-mer probes. Three clones hybridized strongly to both probes. By restriction endonuclease analysis, the three clones were shown to contain the same insert, designated 62A (Fig. 5).

The DNA sequence which hybridized to both probes was narrowed to a 350-bp *Hae*III restriction fragment by digesting the 62A plasmid with *Hae*III, separating the DNA on a 5% polyacrylamide gel, and transferring the DNA from the gel onto nitrocellulose paper for hybridization with each individual probe (data not shown). The 350-bp *Hae*III piece was subcloned into M13mp18, and its sequence was determined. It contains both the 14-mer and 18-mer sequences, and most importantly the DNA has an open reading frame which codes for the 18 amino acids found by sequencing the amino terminus of the P1 protein (Fig. 6). Thus, clone 62A contains the gene for protein P1. However, on the basis of the location of the sequenced *Hae*III fragment in the 62A clone, the 4.3-kb *Hind*III DNA fragment was not large enough to encode the entire 165-kDa P1 protein. Therefore, we used an *Eco*RI-*Pst*I restriction fragment from 62A to clone a larger DNA fragment. The *Eco*RI-*Pst*I piece from 62A was purified, labeled by nick translation, and used as a hybridization probe to clone a 6-kb *Eco*RI fragment of *M. pneumoniae* genome DNA by using the agarose gel procedure described above. Restriction enzyme analysis of this DNA fragment indicated that we had cloned a piece of DNA which overlapped clone 62A and was sufficiently large to encode the entire P1 protein.

Sequence analysis of P1 gene. The nucleotide sequence of much of the 6-kb *Eco*RI fragment was determined and is shown in Fig. 6. There is an open reading frame of 4,881 nucleotides, and at the end of the gene is a TAG stop codon followed by two in-frame TAA stop codons 21 and 27 bp downstream. This sequence could encode for a protein of 1,627 amino acids with a calculated molecular weight of 176,288. The open reading frame contains the 18 amino acids identified by gas phase sequencing (Fig. 6, box). However, instead of being at the amino terminus of the open reading frame, the 18 amino acids are found at positions 60 to 77 of

the deduced protein. The reason for this apparent discrepancy could well be that P1, as for many outer membrane proteins, is initially synthesized as a precursor (25). Consistent with this hypothesis is the observation that the extra 59 amino acids found at the amino terminus of the deduced protein appear like a signal peptide; they include positively charged amino acids followed by a stretch of hydrophobic amino acids (25). If protein P1 is indeed synthesized as a precursor and processed into a mature protein, then the molecular weight of the mature protein would be 169,758, which is very close to the 165 kDa we have reported earlier (1, 17, 18, 23) and almost identical to the value (168 kDa) determined by Jacobs et al. (14) by SDS-PAGE.

The predicted P1 protein has several interesting features: (i) it contains high percentages of hydroxy amino acids (17.7% are serine and threonine); (ii) the protein contains no cysteine; (iii) the TGA codon of tryptophan is slightly preferred over the TGG codon (21:16); and (iv) the high proline content (13 of 26 amino acids) at the carboxy terminus is unusual and may place structural restraints on the protein and assist in regulating the topological organization of the cytoadhesin in the membrane (1, 2, 15, 17). Hydrophilicity plots (9) of the predicted protein sequence suggest several potential antigenic sites (Fig. 7) at positions 240 to 260, 280 to 304, 314 to 333, 450 to 479, 680 to 690, 746 to 767, 898 to 913, 1244 to 1260, and 1476 to 1485. A computer search against existing protein sequence files revealed that the predicted P1 sequence is homologous to coat protein A of bacteriophage I_{ke} (protein P1 amino acid numbers 1308 through 1322 compared with bacteriophage amino acid numbers 240 through 254, 73.3% homology; 257 to 290 versus 231 to 264, 41.2% homology), protein 3A of brome mosaic virus (956 to 979 versus 133 to 159, 52% homology), coat proteins vp2 and vp3 of mouse polyomavirus (733 to 746 versus 24 to 38, 66.7% homology), and coat protein A precursor of bacteriophages fd, M-13, and F1 (1296 to 1330 versus 245 to 280, 51.3% homology). The 1290 to 1350 region of P1 also shares extensive homology with cytoskeletal keratin of mammalian species. In addition, two regions of P1 share extensive homology with human fibrinogen alpha chain precursor (337 to 352 versus 338 to 354, 70.6% homology; 822 to 852 versus 544 to 565, 59.1% homology).

Other relevant features of the sequence include elements upstream of the first ATG codon which are similar to those of typical eubacterial promoters (27). Although the base sequences in these regions are almost identical to those found at -10 and -35 in the consensus *E. coli* α^{70} promoter (27), their separation distance is unusually close (14 bp versus 16 to 18 bp in the *E. coli* promoter). No typical ribosome-binding site is observed between the putative promoter and the proposed initiation codon for translation. Also, an imperfect inverted repeat sequence followed by several thymidines is detected 19 bp downstream from the TAG stop codon. This sequence element is a common feature of RNA terminators (28).

DISCUSSION

Our earlier difficulties in characterizing the P1 cytoadhesin gene (31) prompted us to approach its isolation by obtaining

FIG. 6. Complete nucleotide sequence and deduced amino acid sequence of the P1 gene. The presumed starting codon of P1 (ATG) is numbered as 1. In the 5' flanking region, the possible promoter elements (-10 and -35) are underlined. The 18 amino acids which match those determined by protein sequencing of P1 are boxed (nucleotides 178 to 231). In the 3' flanking region, a sequence with dyad symmetry, which may be a termination signal, is indicated by the arrows, and the asterisk indicates mismatched sequences in this sequence. The complete P1 gene contains 4,881 nucleotides coding for a protein of a calculated 176,288 daltons, which includes an apparent leader peptide (see the text).

AAATCCGTAAGCAAGCAATTAACGCGAGCAAGTACCTTAAAGTATGGTGGGGGGTCAATTCAGCGCCGCGGCT
AGTCTTAAAGCAAGCGGACATTAATCGTGTAGTCAAGATTCGCAAGCAAGCAATTCGCTGTAATTTTAAAGCAAT
30
ATG CAC CAA ACC AAA AAA ACC GGC TGC ACC GGT ACT TGG ATT CTC ATC CTC ACC GGT
Met His Gln Thr Lys Lys Thr Ala Leu Ser Lys Ser Thr Trp Ile Leu Ile Leu Thr Ala
90
ACC GGC TCC CTC GGC ACS GGA CTC ACC GTA GTG GGA CAC TTC ACA AGT ACC ACC ACS AG
Thr Ala Ser Leu Ala Thr Gly Leu Val Val Gly His Phe Thr Ser Thr Thr Thr
120
CTC AAG CAC CAA GAA TTT AGC TAC ACC GGC CCT GAG GAG GTC GGC CTC GGC CAC ACC GGT
Leu Arg Thr Leu Thr Lys Arg Pro Asp Asp Val Ala Leu Leu Thr Arg His Thr Arg
150
GCC ATC AAC CCG GTC TTA ACC CCG TGA AGC TAT GGT AAC ACG ACC TTT TCC TCC CTC CCC
Ala Ile Asn Pro Arg Leu Thr Pro Trp Thr Tyr Arg Asn Thr Ser Phe Ser Ser Ser Leu Pro
210
CTC ACG GGT GAA AAT CCC GGG GCG TGG GGC TTA GTG GGC GAC AAC AGC GCT AAG GCG ATC
Leu Thr Gly Glu Asn Pro Gly Ala Thr Ala Leu Val Arg Asp Asn Ser Ala Lys Gly Ile
270
ACT GGC GGC AGT GGC AGT CAA CAA ACC AGC TAT GAT CCG ACC GCA ACC GAA GCG GCT TGC
Thr Ala Gly Gln Thr Ser Gln Gln Thr Tyr Asp Thr Thr Arg Thr Glu Ala Leu Ile
330
ACC GCA TCA ACC ACC TTT GCG TTA CCG GGG TAT GAC CTC GCG GGC GGC TTA TAC GAC
Thr Ala Ser Thr Thr Phe Ala Leu Arg Arg Tyr Asp Leu Ala Gly Arg Ala Leu Tyr Asp
390
CTC GAT TTT TCG AAG TTA AAC CCG CAA ACC CCG ACC GGC GAC CAA ACC GGG CAG ATC ACC
Leu Asp Phe Ser Lys Leu Asn Pro Gln Thr Pro Thr Arg Asp Gln Thr Gly Gln Ile Thr
450
TTT AAC CCG TTT GCG GGT TTT GGT TTT GGT GGT GGT GGT GGT GGT GGT GGT GGT GGT GGT
Phe Asn Pro Phe Gly Gln Thr Ser Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr
510
AAA AAC AAG GTC CCC CTC GAG GTG GCG CAA GAC CCG TCC AAT CCG TAC CCG TTT GCG GGT
Lys Asn Lys Val Pro Val Glu Val Ala Gln Asp Pro Ser Asn Pro Tyr Arg Phe Ala Val
570
TTA CTC GTG CCG ACC AGC GTC GTG TAC TAT GAG CAG TGC CAA AGC GGG TGG GGC TTA CCA
Leu Leu Val Pro Arg Ser Val Val Tyr Tyr Glu Gln Leu Arg Gly Leu Gly Leu Pro
630
CAG CAC CCA ACC GAG AGT GGT CAA AAT ACT TCC ACC ACC GGG CAA GTG TTT GCG TGC TGC
Gln Gln Arg Thr Gly Gln Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr
690
GTG AAG AAC CCG GAG GCG GAC ACC CCG AAG AGC AAT GAA AAA CTC CAG GCG GCT GAG CCG
Val Lys Asn Ala Glu Ala Asp Thr Ala Lys Ser Asn Glu Lys Leu Gln Gly Ala Glu Ala
750
ACT GGT TCT TCA ACC ACA TCT GGA TCT GGC CAA TCC ACC CAA CCG GGT GGT TCC TCA GCG
Thr Gly Ser Thr Thr Ser Gly Ser Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr
810
CAC ACC AAA CTC AAG GCT TTA AAA ATG GAG GTG AAA AAG AAA TCG GAC TCG GAG CAC AAT
Asp Thr Lys Phe Thr Asp Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr
870
GGT CAG CTG CAG TTA GAA AAA AAT GAT CTC CCG AAC CCG GCT CCG ATT AAG CCG AGC GAG GAG
Gly Gln Leu Gln Leu Glu Lys Asn Asp Leu Ala Asn Ala Pro Ile Lys Arg Ser Glu Glu
930
TCG GGT CAG TCC GTC CAA CTC AAG GCG GAC GAT TTT GGT ACT GCG CTT TCC AGT TCG GGA
Ser Gly Gln Ser Val Gln Leu Lys Ala Asp Asp Phe Thr Thr Thr Thr Thr Thr Thr Thr Thr
990
TCA GGC GGC AAC TCC AAT CCG GGT TCC ACC CCG TGA AGC CCG TGG TTT GCG ACT GAG
Ser Gly Gly Asn Ser Asn Gly Ser Pro Thr Pro Trp Arg Pro Trp Leu Ala Thr Glu
1050
CAA ATT CAC AAG GAC CTC CCC AAA TGA TCC GCG TCG ATT CTC ATT CTC TAT GAG CCG CTT
Gln Ile His Lys Asp Leu Pro Lys Trp Ser Ala Ser Ile Leu Ile Leu Tyr Asp Ala Pro
1110
TAT GCG CCG AAC CCG ACC GGT ATT GAC CCG GGT GAT CAG TGC GAT CCG ACC AGC ATC AGC
Tyr Ala Arg Asn Arg Thr Ala Ile Asp Arg Val Asp His Leu Asp Pro Lys Ala Met Thr
1170
GCG AAC TAT CCG CCG AGT TGA AGA AGC CCG AAG TGA AAC CAC CAC GGT TTT TCG GAG TGA
Ala Asn Tyr Pro Pro Pro Arg Thr Thr Pro Lys Trp Asn His His Gly Leu Trp Asp Thr
1230
AAG GCG CCG GAT GGT TTT CTC CAA ACC ACC GGG TTC AAC CCG CCG CCG CCG CCG GAG
Lys Ala Arg Asp Val Leu Leu Gln Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr
1290
TGG TTT GAT GGC GCG CAG CCG GTC CCG GAT AAC GAA AAG ACC GGG TTT GAT GGT AAC
Trp Phe Asp Gly Gly Gln Thr Val Ala Asp Asn Glu Lys Thr Thr Thr Thr Thr Thr Thr Thr
1350
TCT GAA AAC ACC AAG CCG GGT TTT CAA AAG GAA GCT GAC TCC GAC AAG TCG GCG CCG ATC
Ser Glu Thr Thr Lys Gln Thr Lys Glu Ala Asp Ser Asp Lys Ser Ala Pro Ile
1410
GCG CTC CCG TTT GAA GCG TAC TTC GCG AAC ATT GGC AAC CTC ACC TGG TTT GCG CAA GCG
Ala Leu Thr Phe Glu Ala Tyr Phe Ala Asn Ile Gly Asn Leu Thr Thr Thr Thr Thr Thr Thr Thr
1470
CTT GTC GTC TTT GCG ACC GAT GGT ACC AAG TCG CCG CAC ACC GCG CTT TTT GCG CCG
Leu Leu Val Phe Gly Gly Asn Gly His Val Thr Lys Ser Ala His Thr Ala Pro Leu Ser
1530
ATA GGT GTC TTT AGG GTC CCG TAT AAT GCA ACT GGT ACC AGT GGT ACT GTC ACT GGT TGA
Ile Gly Val Thr Phe Arg Val Arg Tyr Asn Ala Thr Gly Thr Ser Ala Thr Val Thr Thr Thr
1590
CCA TAT GCG TTA CTG TTC TCA GCG ATG GTC AAC AAA CAA ACT CAG GCG TTA AAG GAT CTG
Pro Tyr Ala Leu Leu Phe Ser Gly Met Val Asn Lys Gln Thr Thr Thr Thr Thr Thr Thr Thr
1650
CCC TTT AAC AAT AAC CCG TGT TTT GAA TAT GTA CCA CCG ATG GCA GGT GCT GCG GCT AAG
Pro Phe Asn Asn Asn Arg Trp Phe Glu Tyr Val Pro Arg Met Ala Val Ala Gly Ala Lys
1710
TTC GTT GGT AGG GAA CTC GTT TTA GCG GGT ACC ATT ACC ATG GGT GAT ACC GCT ACC GTA
Phe Val Gly Arg Glu Leu Val Leu Ala Gly Thr Ile Thr Met Gly Asp Thr Ala Thr Val
1770
CCT GCG TTA CTG TAC GAT GAA CTT GAA AGC AAC CTC AAC TTA GTA GCG CAA GCG CAA GGT
Pro Arg Leu Leu Tyr Asp Glu Leu Ser Asn Leu Asn Leu Val Ala Gln Gly Gln Gly
1830
CTT TTA CCG GAA GAC TTA CCA CTC TTC ACA CCG TAC GGA TGA CCG AAT CCG CCG GAT TTA
Leu Leu Arg Glu Asp Leu Gln Leu Phe Thr Pro Tyr Gly Trp Ala Asn Arg Pro Asp Leu
1890
CCA ATC GGG GGT TGA AGT AGT AGT AGT AGT AGT AGT AAC GCA CCA CCC TAC TAC TTC CAC
Pro Ile Gly Ala Trp Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser
1950
AAT AAC CCG GAT TGA CAA GCG CCG CTA ATC CAA AAT GTG GGT GAT GCG TTT ATT AAC CCG
Asn Asn Pro Asp Trp Gln Asp Arg Pro Ile Gln Asn Val Val Asp Ala His Lys Pro
2010
TGA GAG CAG AAC AAG GGT AAG GAT GAT GCG AAA TAC ATC TAC CCG TAC CCG TAC AGT GCG
Trp Glu Asp Lys Asn Gly Lys Asp Asp Ala Lys Tyr Ile Tyr Pro Tyr Arg Tyr Ser Gly
2070
ATG TGA GGT TGA CAG GTA TAC AAC TGG TCC AAT AAG CTC ACT CAG CAA CCA TTA AGT GGT
Met Trp Ala Trp Gln Val Tyr Asn Trp Ser Asn Lys Leu Thr Asp Gln Pro Leu Ser Ala
2130
GAC TTT GGT AAT GAG AAT GCT TAC CAA CCA AAC TCC TTT GCT GCT ATT CTC AAT CCG
Asp Phe Val Asn Glu Asn Ala Tyr Gln Pro Asn Ser Leu Phe Ala Ala Ile Leu Asn Pro
2190
GAA TTT TTA GCA GCT CTT CCC GAC AAG GGT AAA TAC GGT AAG CAA AAC GAG TTT GCT GGT
Glu Leu Leu Ala Ala Glu Leu Pro Asp Lys Val Lys Tyr Gly Lys Glu Asn Glu Phe Ala Ala
2250
AAC GAG TAC GAG CCG TTT AAC CAG AAC TTA CCG GTA GCT CCG ACC CAA GGA ACA TGA
Asn Glu Tyr Glu Arg Phe Asn Gln Lys Leu Thr Val Ala Pro Thr Gln Gly Thr Asn Trp
2310
TCC CAC TTC TCC CCG ACC CTT TCC GGT TTC ACC GGG TTC AAC CTT GTG GGG TCG GCT
Ser His Phe Ser Pro Thr Leu Ser Arg Phe Ser Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr
2370
CTC CAG CAG GTC TGC GAT TAT GTC CCG TGG ATT GGG AAT GGG TAC AGG TAT GCG AAT AAC
Leu Asp Gln Val Leu Asp Tyr Val Pro Trp Ile Gly Asn Gly Tyr Arg Tyr Gly Asn Asn




FIG. 7. Plot of hydrophilicity value versus sequence position of P1 according to the method of Hopp and Woods (9). Hydrophilicity values are averaged over six amino acids through the length of P1; highest positive values represent charged hydrophilic regions.

a partial amino acid sequence of protein P1 and then synthesizing two oligonucleotides (14-mer and 18-mer) complementary to the corresponding gene in order to identify appropriate clones. Because of the small size of the *M. pneumoniae* genome (approximately 800 kb), we calculated that sequences which hybridized to the 14-mer or 18-mer probes should occur only one or two times. If the same piece of *M. pneumoniae* DNA hybridized to both 14-mer and 18-mer probes, this DNA fragment should contain the sequence coding for the amino terminus of P1. The 4.3-kb *Hind*III piece of *M. pneumoniae* (Fig. 4 to 6) contains the appropriate P1 gene sequence not only because it hybridizes to both 14-mer and 18-mer probes, but also because it codes for all 18 amino acids determined from the N-terminal sequencing of the purified P1 protein. Of interest is the observation that the 10th amino acid that we sequenced from the N terminus is a tryptophan, which further suggests that if *E. coli* uses the P1 promoter sequence, the protein might be terminated prematurely.

From the nucleotide sequences, a possible translational initiation site ATG occurs in frame, which is 177 nucleotides from the P1 N-terminal sequence. There are conventional transcription initiation sites at -35 and -10 upstream with a distance of 14 nucleotides between these two consensus sequences (27), but no ribosome-binding site is observed between -10 and the initiation codon. This predicts a protein with an extension of 59 amino acids from the N terminus. Another possible translational initiation codon is the GTG (7) at position 91. Use of this initiation site would predict a 28-amino-acid precursor. Since all of the predictions are made on the basis of the study of *E. coli* and other procaryotic organisms and no information about mycoplasma promoter or initiation sites is available, further study is needed to determine the precise transcriptional and translational initiation sites.

The predicted P1 gene sequence is consistent with available information about protein P1: (i) the predicted molecular weight of P1 approximates the reported values; (ii) the predicted N-terminal amino acid sequence fits exactly with the gas phase sequence analysis of purified P1 protein; (iii) the predicted P1 sequence contains more basic amino acids (Arg + Lys + His = 169) than acidic (Asp + Glu = 143) (our unpublished isoelectric focusing data show that P1 has an isoelectric point at a basic pH); (iv) the predicted P1 has no intramolecular disulfide bonding, which correlates with our

previous observation that the P1 position in polyacrylamide gels is not changed after exposure to sample buffer containing reducing agents.

Since cytoadhesin P1 is strongly immunogenic based upon humoral immune response data in humans and hamsters (19) and the appearance of anti-P1 antibodies correlates with resolution of the infection (19), we are interested in identifying the antigenic sites which may serve as effective vaccine candidates. The hydrophilicity plot (Fig. 7) implicates several potential sites. It is fascinating that parts of the P1 sequence are homologous to specific viral coat proteins and mammalian cytoskeletal keratin as well as the human fibrinogen alpha chain precursor, which may relate to previous observations of autoimmune-like mechanisms of pathophysiology associated with mycoplasma disease (4, 33).

Now that the gene sequence of *M. pneumoniae* cytoadhesin P1 has been delineated and its protein sequence has been deduced, we can begin to address other relevant issues. Do gene duplications or rearrangements of the P1 gene occur? Why does P1 lose functionality as an adhesin after brief protease treatment? What factors regulate the mobilization and clustering of P1 at the tip organelle, and what is the basis for the cooperative interactions between P1 and other membrane proteins (1, 17)? Will synthetic peptides which substitute for the immunologically and functionally relevant domains of P1 serve as effective vaccine candidates and diagnostic probes? Can the available P1 gene and protein data assist in characterizing the immunologically related 140-kDa protein (23) of the newly discovered human pathogen, *Mycoplasma genitalium* (32)? In addition, identification of the host cell receptor(s) which mediates *M. pneumoniae* cytoadherence in the respiratory tract has been elusive, and information provided by the P1 sequence may assist in defining tissue tropism at the molecular level.

ACKNOWLEDGMENTS

We thank Rose Garza for her expert secretarial assistance.

This research was supported in part by Public Health Service grant AI 18540 from The National Institute of Allergy and Infectious Diseases.

LITERATURE CITED

- Baseman, J. B., R. M. Cole, D. C. Krause, and D. K. Leith. 1982. Molecular basis for cytoadsorption of *Mycoplasma pneumoniae*. *J. Bacteriol.* **151**:1514-1522.
- Baseman, J. B., D. L. Drouillard, D. K. Leith, and J. Morrison-Plummer. 1985. Role of *Mycoplasma pneumoniae* adhesin P1 and accessory proteins in cytoadsorption, p. 18-23. In S. E. Mergenhagen and B. Rosan (ed.), *Molecular basis of oral microbial adhesion*. American Society for Microbiology, Washington, D.C.
- Berent, S. L., M. Mahmoudi, R. M. Torczynski, P. W. Bragg, and A. P. Bollon. 1985. Comparison of oligonucleotide and long DNA fragments as probes in DNA and RNA dot, Southern, Northern, colony and plaque hybridizations. *Biotechnology* **3**:208-220.
- Biberfeld, G. 1971. Antibodies to brain and other tissues in cases of *Mycoplasma pneumoniae* infection. *Clin. Exp. Immunol.* **8**:319-333.
- Collier, A. M., and J. B. Baseman. 1973. Organ culture techniques with mycoplasmas. *Ann. N.Y. Acad. Sci.* **225**:277-289.
- Feldner, J., U. Gobel, and W. Bredt. 1982. *Mycoplasma pneumoniae* adhesin localized to tip structure by monoclonal antibody. *Nature (London)* **298**:765-767.
- Gold, L., D. Pribnow, T. Schneider, S. Shinedling, B. S. Singer, and G. Stormo. 1981. Translational initiation in prokaryotes. *Annu. Rev. Microbiol.* **35**:365-403.
- Henikoff, S. 1984. Unidirectional digestion with exonuclease III

- creates targeted breakpoints for DNA sequencing. *Gene* **28**:351–359.
9. Hopp, T. P., and K. R. Woods. 1981. Prediction of protein antigenic determinants from amino acid sequences. *Proc. Natl. Acad. Sci. USA* **78**:3824–3828.
 10. Hu, P. C., R. M. Cole, Y. S. Huang, J. A. Graham, D. E. Gardner, A. M. Collier, and W. A. Clyde. 1982. *Mycoplasma pneumoniae* infection: role of a surface protein in the attachment organelle. *Science* **216**:313–315.
 11. Hu, P. C., A. M. Collier, and J. B. Baseman. 1977. Surface parasitism by *Mycoplasma pneumoniae* of respiratory epithelium. *J. Exp. Med.* **145**:1328–1343.
 12. Hunkapiller, M. W., E. Lujan, F. Ostrander, and L. E. Hood. 1983. Isolation of microgram quantities of proteins from polyacrylamide gels for amino acid sequence analysis. *Methods Enzymol.* **91**:227–236.
 13. Ish-Horowicz, D., and J. F. Burke. 1981. Rapid and efficient cosmid vector cloning. *Nucleic Acids Res.* **9**:2989–2998.
 14. Jacobs, E., A. Bennewitz, and W. Brecht. 1986. Reaction pattern of human anti-*Mycoplasma pneumoniae* antibodies in enzyme-linked immunosorbent assays and immunoblotting. *J. Clin. Microbiol.* **23**:517–522.
 15. Kahane, I., S. Tucker, and J. B. Baseman. 1985. Detection of *Mycoplasma pneumoniae* adhesin (P1) in the nonhemadsorbing population of virulent *Mycoplasma pneumoniae*. *Infect. Immun.* **49**:457–458.
 16. Krause, D. C., D. K. Leith, and J. B. Baseman. 1983. Reacquisition of specific proteins confers virulence in *Mycoplasma pneumoniae*. *Infect. Immun.* **39**:830–836.
 17. Krause, D. C., D. K. Leith, R. M. Wilson, and J. B. Baseman. 1982. Identification of *Mycoplasma pneumoniae* proteins associated with hemadsorption and virulence. *Infect. Immun.* **35**:809–817.
 18. Leith, D. K., and J. B. Baseman. 1984. Purification of a *Mycoplasma pneumoniae* adhesin by monoclonal antibody affinity chromatography. *J. Bacteriol.* **157**:678–680.
 19. Leith, D. K., L. B. Trevino, J. G. Tully, L. B. Senterfit, and J. B. Baseman. 1983. Host discrimination of *Mycoplasma pneumoniae* proteinaceous immunogens. *J. Exp. Med.* **157**:502–514.
 20. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. *Molecular cloning: a laboratory manual*. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
 21. Messing, J., R. Crea, and P. H. Seeberg. 1981. A system for shotgun DNA sequencing. *Nucleic Acids Res.* **9**:309–321.
 22. Mizusawa, S., S. Nishimura, and F. Seela. 1986. Improvement of the dideoxy chain termination method of DNA sequencing by use of deoxy-7-deazaguanosine triphosphate in place of dGTP. *Nucleic Acids Res.* **14**:1319–1324.
 23. Morrison-Plummer, J., A. Lazzell, and J. B. Baseman. 1987. Shared epitopes between *Mycoplasma pneumoniae* major adhesin protein P1 and a 140-kilodalton protein of *Mycoplasma genitalium*. *Infect. Immun.* **55**:49–56.
 24. Morrison-Plummer, J., D. K. Leith, and J. B. Baseman. 1986. Biological effects of anti-lipid and anti-protein monoclonal antibodies on *Mycoplasma pneumoniae*. *Infect. Immun.* **53**:398–403.
 25. Oliver, D. 1985. Protein secretion in *Escherichia coli*. *Annu. Rev. Microbiol.* **39**:615–648.
 26. Powell, D. A., P. C. Hu, M. Wilson, A. M. Collier, and J. B. Baseman. 1976. Attachment of *Mycoplasma pneumoniae* to respiratory epithelium. *Infect. Immun.* **13**:959–966.
 27. Reznikoff, W. S., D. A. Siegele, D. W. Cowing, and C. A. Gross. 1985. The regulation of transcription initiation in bacteria. *Annu. Rev. Genet.* **19**:355–387.
 28. Rosenberg, M., and P. Court. 1979. Regulatory sequence involved in the promotion and termination of RNA transcription. *Annu. Rev. Genet.* **13**:319–353.
 29. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA* **74**:5463–5467.
 30. Southern, E. M. 1975. Detection of specific sequences among DNA fragments separated by gel electrophoresis. *J. Mol. Biol.* **98**:503–517.
 31. Trevino, L. B., W. G. Haldenwang, and J. B. Baseman. 1986. Expression of *Mycoplasma pneumoniae* antigens in *Escherichia coli*. *Infect. Immun.* **53**:129–134.
 32. Tully, J. G., D. Taylor-Robinson, R. M. Cole, and D. L. Rose. 1981. A newly discovered mycoplasma in the human urogenital tract. *Lancet* **i**:1288–1291.
 33. Wise, K. S., and R. K. Watson. 1985. Antigenic mimicry of mammalian intermediate filaments by mycoplasmas. *Infect. Immun.* **48**:587–591.
 34. Wood, W. I., J. Gitschier, L. A. Lasky, and R. M. Lawn. 1985. Base composition-independent hybridization in tetramethylammonium chloride. A method for oligonucleotide screening of highly complex gene libraries. *Proc. Natl. Acad. Sci. USA* **82**:1585–1588.
 35. Yamao, F., A. Muto, Y. Kawauchi, M. Iwami, S. Iwagami, Y. Azumi, and S. Osawa. 1985. UGA is read as tryptophan in *Mycoplasma capricolum*. *Proc. Natl. Acad. Sci. USA* **82**:2306–2309.